clinical trial · NCT07908004
A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People
HealthyBI 3821001Placebo
brief summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3821001 administrations of multiple rising doses.
started
Nov 3, 2026
primary completion
Jun 22, 2027
completion
Jun 28, 2027
last updated
Nov 12, 2026
official title
A Phase I Single-blind, Randomised, Placebo-controlled, Parallel Group Design Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 3821001 Administered to Healthy Trial Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol